Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NW-301V and NW-301D in Advanced Solid Tumors
NCT06956261Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NW-301V and NW-301D in pancreatic cancer (PC), colorectal cancer (CRC) and lung adenocarcinoma (2 arms), sponsored by Peking University. Primary endpoint: Dose-limiting toxicity at 28 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
NW-301VNW-301D
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)lung adenocarcinoma
Beyond the preview
Go deeper on NCT06956261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956261.